Sun Pharma grows revenue 10.50 percent: Sun Pharma stock sits 14.7 percent below high

Published on 10/14/2026 at 13:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Margin reached 28.10 percent in first-quarter fiscal 2027. Sun Pharma stock costs INR 1,746.40 on October 14, 2026, down 1.37 percent on NSE.

Revenue and valuation overview

Sun Pharma reported INR 153.00 billion of first-quarter fiscal 2027 revenue, up 10.50 percent year on year.
Operating margin reached 28.10 percent in the first quarter of fiscal 2027 after the prior-year one-off Lenalidomide contribution.
Sun Pharma stock costs INR 1,746.40 at 3:29 p.m. IST on October 14, 2026, down 1.37 percent versus the NSE close of October 13, 2026.
The stock trades at a P/E of 34.64 and has a market capitalization of INR 4.2 trillion as of October 14, 2026.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

DSIJ reported that Sun Pharma revenue rose 10.50 percent year on year to INR 153.00 billion in the first quarter of fiscal 2027, while Sun Pharma stock sat 14.70 percent below its INR 2,046.90 52-week high. Sun Pharma stock last stood at INR 1,746.40 on October 14, 2026 at 3:29 p.m. IST, down 1.37 percent on NSE versus the October 13, 2026 close of INR 1,770.70.

Revenue growth meets margin pressure

The first-quarter revenue comparison is positive, but the earnings mix matters. DSIJ reported operating profit of INR 42.96 billion, up 5.50 percent year on year, while the operating margin was 28.10 percent, down 130 basis points from the prior-year quarter.

The margin comparison includes a clear one-off factor. DSIJ said the prior-year period benefited from a contribution from Lenalidomide sales, making the current margin base less favorable even as revenue expanded.

Stock stays below its yearly high

The NSE quote places the stock at INR 1,746.40, which is 10.28 percent above the 52-week low of INR 1,583.70 and 14.70 percent below the high of INR 2,046.90. Trading volume was 1,967,125 shares against an average volume of 1,853,538 shares.

The market move also separates Sun Pharma from its recent operating growth. Business Standard reported on October 14, 2026 that regulatory risk, US pricing pressure and generic competition remain important factors for the company.

Valuation and peer comparison

Sun Pharma had a market capitalization of INR 4.2 trillion, a P/E of 34.64 and a dividend yield of 0.01 percent as of October 14, 2026. The valuation is higher than the two selected Indian pharmaceutical peers in the same market data snapshot.

Comparison with peers

Sun Pharma (NSE, INR): minus 1.37 percent, P/E 34.64, market capitalization INR 4.2 trillion

Dr. Reddy's Laboratories (NSE, INR): minus 1.94 percent, P/E 30.62, market capitalization INR 1.0 trillion

Cipla (NSE, INR): minus 1.13 percent, P/E 31.53, market capitalization INR 1.1 trillion

Price position remains measurable

Sun Pharma stock last stood at INR 1,746.40 on October 14, 2026 at 3:29 p.m. IST, down 1.37 percent from the NSE close of October 13, 2026 at INR 1,770.70. The stock remained 14.70 percent below its 52-week high, leaving the first-quarter revenue and margin figures as the main operating reference points.